Clinical Trials Browser

Phase 1 × durvalumab × 30 days × Clear all

NCT07391670 2026-04-17

IMFINZI-subQ

Phase 1 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma

NCT07531095 2026-04-15

DeLLphi-313

Phase 1 Not yet recruiting

Small Cell Lung Carcinoma

NCT04686305 2026-04-13

DL03

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05411094 2026-04-13

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Phase 1 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04612751 2026-04-06

TROPION-Lung04

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07107750 2026-04-03

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Phase 1 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT03923270 2026-04-01

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Phase 1 Active not recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT02537418 2026-03-27

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Phase 1 Active not recruiting

Solid Malignancies

NCT02997332 2026-03-23

MEDINDUCTION

Phase 1 Terminated

Head and Neck Neoplasms

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Active not recruiting

Skin Neoplasms